Form 4: Vir Biotechnology Director Transfers Shares for Tax Planning

George A. Scangos, a director at Vir Biotechnology, reported transferring shares of common stock for tax planning purposes.

Summary

• On October 23, 2024, George A. Scangos, a director of Vir Biotechnology, Inc., filed a Form 4 indicating changes in his beneficial ownership of the company's common stock.
• The transactions involved the transfer of shares without consideration for tax planning purposes.
• Specifically, 598,270 shares were transferred into and out of various trusts associated with Scangos and his family.
• Following these transactions, Scangos directly owns 719,259 shares.
• He also indirectly owns 1,151,730 shares through the George A Scangos 2023 Annuity Trust, 598,270 shares through his spouse, 1,151,730 shares through the Leslie Wilson 2023 Annuity Trust, 33,629 shares through the Scangos-Wilson Family Trust, and 179,930 shares through the Scangos 2018 Grandchildren's Trust.

Sentiment

Score: 5

Explanation: This is a neutral filing related to standard insider transactions for tax planning purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates